Yttrium-90 - current status, expected availability and applications of a high beta energy emitter

R. Leyva Montaña, I. Hernández González, A. Alberti Ramirez, L. Garaboldi, M. Chinol

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Yttrium-90 (90Y, T1/2 64.14 h) is a key example of a high beta energy-emitting radionuclide which is available from the strontium-90 (90Sr)/90Y radionuclide generator system. Clinical uses of 90Y-labeled radiopharmaceutical agents have been pursued for many years and many applications have proven to be clinical effective. These most notably include the application of 90Y-labeled antibodies for a variety of applications such as for effective treatment of non-Hodgkin's lymphoma. One of the major advantages for use of 90Y is ready availability from the very long-lived 90Sr parent (T1/2 28.78 y). Because of the importance of maintaining generator performance and minimizing parent breakthrough, this paper describes development, use and quality control of both high capacity cation adsorption-type and electrochemical generator systems. In addition, the preparation and targeting to tumors in mice of DOTA-conjugated Nimotuzamab (h-R3) antibody which recognizes the external domain of the EPFR antibody radiolabeled with 90Y obtained from the electrochemical generator is also described. As a key example for clinical applications of 90Y, the use of 90Y-labeled biotin for intra-operative pre-targeting for radionuclide therapy (IART®) of breast cancer is also described.

Original languageEnglish
Pages (from-to)253-263
Number of pages11
JournalCurrent Radiopharmaceuticals
Volume5
Issue number3
Publication statusPublished - Jul 2012

Fingerprint

Yttrium
Radioisotopes
Radionuclide Generators
Antibodies
Strontium
Radiopharmaceuticals
Biotin
Quality Control
Non-Hodgkin's Lymphoma
Adsorption
Cations
Breast Neoplasms
Neoplasms
Therapeutics

Keywords

  • Sr impurity
  • Sr/Y generators
  • Antibody radiolabeling
  • Biotin radiolabeling
  • Pre-targeting approach

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Leyva Montaña, R., Hernández González, I., Alberti Ramirez, A., Garaboldi, L., & Chinol, M. (2012). Yttrium-90 - current status, expected availability and applications of a high beta energy emitter. Current Radiopharmaceuticals, 5(3), 253-263.

Yttrium-90 - current status, expected availability and applications of a high beta energy emitter. / Leyva Montaña, R.; Hernández González, I.; Alberti Ramirez, A.; Garaboldi, L.; Chinol, M.

In: Current Radiopharmaceuticals, Vol. 5, No. 3, 07.2012, p. 253-263.

Research output: Contribution to journalArticle

Leyva Montaña, R, Hernández González, I, Alberti Ramirez, A, Garaboldi, L & Chinol, M 2012, 'Yttrium-90 - current status, expected availability and applications of a high beta energy emitter', Current Radiopharmaceuticals, vol. 5, no. 3, pp. 253-263.
Leyva Montaña R, Hernández González I, Alberti Ramirez A, Garaboldi L, Chinol M. Yttrium-90 - current status, expected availability and applications of a high beta energy emitter. Current Radiopharmaceuticals. 2012 Jul;5(3):253-263.
Leyva Montaña, R. ; Hernández González, I. ; Alberti Ramirez, A. ; Garaboldi, L. ; Chinol, M. / Yttrium-90 - current status, expected availability and applications of a high beta energy emitter. In: Current Radiopharmaceuticals. 2012 ; Vol. 5, No. 3. pp. 253-263.
@article{47e2cb46581741928e4d97de9b736d11,
title = "Yttrium-90 - current status, expected availability and applications of a high beta energy emitter",
abstract = "Yttrium-90 (90Y, T1/2 64.14 h) is a key example of a high beta energy-emitting radionuclide which is available from the strontium-90 (90Sr)/90Y radionuclide generator system. Clinical uses of 90Y-labeled radiopharmaceutical agents have been pursued for many years and many applications have proven to be clinical effective. These most notably include the application of 90Y-labeled antibodies for a variety of applications such as for effective treatment of non-Hodgkin's lymphoma. One of the major advantages for use of 90Y is ready availability from the very long-lived 90Sr parent (T1/2 28.78 y). Because of the importance of maintaining generator performance and minimizing parent breakthrough, this paper describes development, use and quality control of both high capacity cation adsorption-type and electrochemical generator systems. In addition, the preparation and targeting to tumors in mice of DOTA-conjugated Nimotuzamab (h-R3) antibody which recognizes the external domain of the EPFR antibody radiolabeled with 90Y obtained from the electrochemical generator is also described. As a key example for clinical applications of 90Y, the use of 90Y-labeled biotin for intra-operative pre-targeting for radionuclide therapy (IART{\circledR}) of breast cancer is also described.",
keywords = "Sr impurity, Sr/Y generators, Antibody radiolabeling, Biotin radiolabeling, Pre-targeting approach",
author = "{Leyva Monta{\~n}a}, R. and {Hern{\'a}ndez Gonz{\'a}lez}, I. and {Alberti Ramirez}, A. and L. Garaboldi and M. Chinol",
year = "2012",
month = "7",
language = "English",
volume = "5",
pages = "253--263",
journal = "Current Radiopharmaceuticals",
issn = "1874-4710",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Yttrium-90 - current status, expected availability and applications of a high beta energy emitter

AU - Leyva Montaña, R.

AU - Hernández González, I.

AU - Alberti Ramirez, A.

AU - Garaboldi, L.

AU - Chinol, M.

PY - 2012/7

Y1 - 2012/7

N2 - Yttrium-90 (90Y, T1/2 64.14 h) is a key example of a high beta energy-emitting radionuclide which is available from the strontium-90 (90Sr)/90Y radionuclide generator system. Clinical uses of 90Y-labeled radiopharmaceutical agents have been pursued for many years and many applications have proven to be clinical effective. These most notably include the application of 90Y-labeled antibodies for a variety of applications such as for effective treatment of non-Hodgkin's lymphoma. One of the major advantages for use of 90Y is ready availability from the very long-lived 90Sr parent (T1/2 28.78 y). Because of the importance of maintaining generator performance and minimizing parent breakthrough, this paper describes development, use and quality control of both high capacity cation adsorption-type and electrochemical generator systems. In addition, the preparation and targeting to tumors in mice of DOTA-conjugated Nimotuzamab (h-R3) antibody which recognizes the external domain of the EPFR antibody radiolabeled with 90Y obtained from the electrochemical generator is also described. As a key example for clinical applications of 90Y, the use of 90Y-labeled biotin for intra-operative pre-targeting for radionuclide therapy (IART®) of breast cancer is also described.

AB - Yttrium-90 (90Y, T1/2 64.14 h) is a key example of a high beta energy-emitting radionuclide which is available from the strontium-90 (90Sr)/90Y radionuclide generator system. Clinical uses of 90Y-labeled radiopharmaceutical agents have been pursued for many years and many applications have proven to be clinical effective. These most notably include the application of 90Y-labeled antibodies for a variety of applications such as for effective treatment of non-Hodgkin's lymphoma. One of the major advantages for use of 90Y is ready availability from the very long-lived 90Sr parent (T1/2 28.78 y). Because of the importance of maintaining generator performance and minimizing parent breakthrough, this paper describes development, use and quality control of both high capacity cation adsorption-type and electrochemical generator systems. In addition, the preparation and targeting to tumors in mice of DOTA-conjugated Nimotuzamab (h-R3) antibody which recognizes the external domain of the EPFR antibody radiolabeled with 90Y obtained from the electrochemical generator is also described. As a key example for clinical applications of 90Y, the use of 90Y-labeled biotin for intra-operative pre-targeting for radionuclide therapy (IART®) of breast cancer is also described.

KW - Sr impurity

KW - Sr/Y generators

KW - Antibody radiolabeling

KW - Biotin radiolabeling

KW - Pre-targeting approach

UR - http://www.scopus.com/inward/record.url?scp=84863557048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863557048&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 253

EP - 263

JO - Current Radiopharmaceuticals

JF - Current Radiopharmaceuticals

SN - 1874-4710

IS - 3

ER -